Role of pharmacists in adherence in oncology patients

References

• Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44–47. doi: 10.1111/j.1524-4733.2007.00213.x.
   PubMed Web of Science ®Google Scholar
• Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009;59(1):56–66. doi: 10.3322/caac.20004.
   PubMed Web of Science ®Google Scholar
• Marin D, Bazeos A, Mahon F-X, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28(14):2381–2388. doi: 10.1200/JCO.2009.26.3087.
   PubMed Web of Science ®Google Scholar
• Verbrugghe M, Verhaeghe S, Lauwaert K, et al. Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: a systematic review. Cancer Treat Rev. 2013;39(6):610–621. doi: 10.1016/j.ctrv.2012.12.014.
   PubMed Web of Science ®Google Scholar
• Bassan F, Peter F, Houbre B, et al. Adherence to oral antineoplastic agents by cancer patients: definition and literature review. Eur J Cancer Care (Engl). 2014;23(1):22–35. doi: 10.1111/ecc.12124.
   PubMed Web of Science ®Google Scholar
• Jacobs JM, Pensak NA, Sporn NJ, et al. Treatment satisfaction and adherence to oral chemotherapy in patients with cancer. J Oncol Pract. 2017;13(5):e474–e485. doi: 10.1200/JOP.2016.019729.
   PubMed Web of Science ®Google Scholar
• Kwon J, Ledvina D, Newton M, et al. Oncology pharmacy education and training in the United States schools of pharmacy. Curr Pharm Teach Learn. 2015;7(4):451–457. doi: 10.1016/j.cptl.2015.04.005.
   Google Scholar
• Paolella GA, Boyd AD, Wirth SM, et al. Adherence to oral anticancer medications: evolving interprofessional roles and pharmacist workforce considerations. Pharmacy (Basel). 2018;6(1):23. doi: 10.3390/pharmacy6010023.
   PubMedGoogle Scholar
• Benbrahim N, Garcia-Cardenas V, Saez-Benito L, et al. Adherence: a review of education, research, practice and policy in Spain. Pharm Pract. 2009;7(3):125–138.
   PubMedGoogle Scholar
• Dircks M, Mayr A, Freidank A, et al. Advances in clinical pharmacy education in Germany: a quasi-experimental single-blinded study to evaluate a patient-centred clinical pharmacy course in psychiatry. BMC Med Educ. 2017;17(1):251. doi: 10.1186/s12909-017-1092-z.
   PubMedGoogle Scholar
• Fentie A, Huluka S, Gebremariam G, et al. Impact of pharmacist-led interventions on medication-related problems among patients treated for cancer: a systematic review and meta-analysis of randomized control trials. Res Social Adm Pharm. 2024;20(5):487–497. doi: 10.1016/j.sapharm.2024.02.006.
   PubMed Web of Science ®Google Scholar
• Dimitrova M, Jakab I, Mitkova Z, et al. Potential barriers of patient involvement in health technology assessment in Central and Eastern european countries. Front Public Health. 2022;10:922708. doi: 10.3389/fpubh.2022.922708.
   PubMed Web of Science ®Google Scholar
• Arksey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19–32. doi: 10.1080/1364557032000119616.
   Google Scholar
• Levac D, Colquhoun H, O’Brien KK. Scoping studies: advancing the methodology. Implement Sci. 2010;5(1):69. (doi: 10.1186/1748-5908-5-69.
   PubMed Web of Science ®Google Scholar
• Hansen EA, Pietkiewicz JM, Blum BL. Evaluation of the feasibility and utility of a pharmacist-centered collaborative drug therapy management program for oncology-based symptom management. J Pharm Pract. 2016;29(3):206–211. doi: 10.1177/0897190014557626.
   PubMedGoogle Scholar
• Djebbari F, Stoner N, Lavender VT. A systematic review of non-standard dosing of oral anticancer therapies. BMC Cancer. 2018;18(1):1154. doi: 10.1186/s12885-018-5066-2.
   PubMedGoogle Scholar
• Birand N, Boşnak AS, Diker Ö, et al. The role of the pharmacist in improving medication beliefs and adherence in cancer patients. J Oncol Pharm Pract. 2019;25(8):1916–1926. doi: 10.1177/1078155219831377.
   PubMed Web of Science ®Google Scholar
• Defoe KD, Jupp J, Leslie T. Integration of clinical pharmacists into an ambulatory, pediatric hematology/oncology/transplant clinic. J Oncol Pharm Pract. 2019;25(3):607–612. doi: 10.1177/1078155217752534.
   PubMed Web of Science ®Google Scholar
• Mackler E, Segal EM, Muluneh B, et al. 2018 Hematology/oncology pharmacist association best practices for the management of oral oncolytic therapy: pharmacy practice standard. J Oncol Pract. 2019;15(4):e346–e355. doi: 10.1200/JOP.18.00581.
   PubMed Web of Science ®Google Scholar
• Holle LM, Segal EM, Jeffers KD. The expanding role of the oncology pharmacist. Pharmacy (Basel). 2020;8(3):130. doi: 10.3390/pharmacy8030130.
   PubMedGoogle Scholar
• Crul M, Oosterhof P. The oncology pharmacist as part of the palliative treatment team. Int J Pharm Pract. 2020;28(1):92–96. doi: 10.1111/ijpp.12583.
   PubMed Web of Science ®Google Scholar
• Joy AM, Nandakumar UP, Sharad C, et al. Role of clinical pharmacist in the medication adherence behaviour of cancer patients: an interventional study. Pharm Hosp Clin. 2021;56(3):291–297. doi: 10.1016/j.phclin.2021.05.002.
   Google Scholar
• Pirolli AV, Brusamarello T, Everton SS, et al. The role of the clinical pharmacist in guiding adjuvant hormonal therapy in patients with breast cancer. J Oncol Pharm Pract. 2022;28(6):1368–1374. doi: 10.1177/10781552211029361.
   PubMed Web of Science ®Google Scholar
• Ghiggia A, Bianco A, Castelli L, et al. Adherence to oral chemotherapy: evidence from a randomised clinical trial. Eur J Cancer Care (Engl). 2021;30(1):e13336. doi: 10.1111/ecc.13336.
   PubMed Web of Science ®Google Scholar
• Oliveira CS, Silva MP, Miranda Í, et al. Impact of clinical pharmacy in oncology and hematologycenters: a systematic review. J Oncol Pharm Pract. 2021;27(3):679–692. doi: 10.1177/1078155220976801.
   PubMed Web of Science ®Google Scholar
• Neuner J, Weil E, Fergestrom N, et al. Feasibility of a pharmacist-led symptom monitoring and management intervention to improve breast cancer endocrine therapy adherence. J Am Pharm Assoc (2003). 2022;62(4):1321–1328.e3. doi: 10.1016/j.japh.2022.03.001.
   PubMed Web of Science ®Google Scholar
• Novosadova M, Filip S, Molnarova V, et al. Clinical pharmacist in oncology palliative medicine: drug compliance and patient adherence. BMJ Support Palliat Care. 2023;13(e3):e1308–e1317. doi: 10.1136/spcare-2023-004212.
   Web of Science ®Google Scholar
• Al-Taie A, Izzettin FV, Sancar M, et al. Impact of clinical pharmacy recommendations and patient counselling program among patients with diabetes and cancer in outpatient oncology setting. Eur J Cancer Care (Engl). 2020;29(5):e13261. doi: 10.1111/ecc.13261.
   PubMed Web of Science ®Google Scholar
• Carolyn SJM. Role of pharmacists in optimizing the use of anticancer drugs in the clinical setting. IPRP. 2014;3:11–24. doi: 10.2147/IPRP.S40428.
   Google Scholar
• Krikorian S, Pories S, Tataronis G, et al. Adherence to oral chemotherapy: challenges and opportunities. J Oncol Pharm Pract. 2019;25(7):1590–1598. doi: 10.1177/1078155218800384.
   PubMed Web of Science ®Google Scholar
• Umar RM, Apikoglu-Rabus S, Yumuk PF. Significance of a clinical pharmacist-led comprehensive medication management program for hospitalized oncology patients. Int J Clin Pharm. 2020;42(2):652–661. doi: 10.1007/s11096-020-00992-8.
   PubMed Web of Science ®Google Scholar
• Qi H, Zhu L, Chen L, et al. Reduced emergency room visits and improved medication adherence of an integrated oncology pharmaceutical care practice in China. J Oncol Pharm Pract. 2021;27(6):1503–1515. doi: 10.1177/10781552211027218.
   PubMed Web of Science ®Google Scholar